Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-110	-91.29	-55.72
Net Income Net Income Growth	-103.31	-85.2	-49.74
Earnings Per Share EPS Growth	-12.34	-87.74	-184.14
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	413.53	138.41	118.12
Total Debt Total Debt Growth	17.11	1.67	-
Net Cash (Debt) Net Cash Growth	396.42	136.74	118.12
Net Cash Growth	-	15.76%	-
Net Cash Per Share Net Cash Per Share Growth	47.34	140.82	437.25

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-97.48	-81.48	-48.37
Capital Expenditures CapEx Growth	-0.92	-0.34	-0.1
Free Cash Flow Free Cash Flow Growth	-98.4	-81.83	-48.46
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 18, 2026

Data Sources Report a data error